Eli Lilly’s latest Phase III data on retatrutide, which surpassed Novo Nordisk (CPSE:NOVO B) drug Ozempic on weight loss and blood sugar control, has sharpened investor focus on Novo’s long term GLP-1 positioning.
The Novo Nordisk share price has been volatile this year. A recent 1-day share price return of 2.1% to DKK260.35 offered only a brief pause in a wider reset that includes a 30-day share price gain of 3.5%, a 90-day share price decline of 15.1%, and a year-to-date share price drop of 21.2%. Over a longer horizon, the 1-year total shareholder return is down 15.5% and the 3-year total shareholder return has fallen 60.0%, as fresh GLP-1 competition, new data presentations, and product approvals such as once-weekly Awiqli shape how investors reassess both growth potential and risk around the wider obesity and diabetes franchise.
Scan how Novo Nordisk’s GLP-1 reset compares with other potential breakout opportunities in obesity and metabolic health through our curated list of 130 healthcare AI stocks.
Novo Nordisk now trades at DKK260.35 with analyst targets and intrinsic estimates pointing higher, yet recent GLP-1 shocks still weigh on sentiment. Where does fair value truly land inside that spread?
Most Popular Narrative: 69% Undervalued
The most followed valuation view on Novo Nordisk estimates fair value at DKK851, well above the last close at DKK260.35. This creates a wide gap that investors are trying to make sense of.
Novo Nordisk has built a formidable economic moat ("Burggraben") through decades of expertise in diabetes care, world-class manufacturing, and a trusted global brand. With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free, built on the same scientific platform. This windfall is now driving massive capital inflows, which Novo Nordisk is wisely reinvesting to secure its leadership for decades to come.
See why 101 investors see Novo Nordisk as 69% undervalued.
Result: Fair Value of DKK851 (UNDERVALUED)
Still, this bullish Novo Nordisk narrative could be challenged if GLP-1 pricing pressure intensifies or if new obesity and diabetes competitors gain faster traction than expected.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
Feeling mixed about Novo Nordisk after all of this, or seeing a clearer story in the numbers? Move quickly from headline reactions to hard evidence by weighing the full balance of risks and rewards in the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Novo Nordisk?
If Novo Nordisk has sharpened your focus on quality and risk, do not stop here. Broaden your watchlist now or you may overlook your next strong performer.
- To target resilient wealth compounding, focus on businesses that generate cash and trade below intrinsic value through the 194 high quality undervalued stocks.
- To seek income potential, focus on companies with robust payout profiles and higher yields using the 228 dividend fortresses.
- To support downside protection, prioritise financially durable businesses that appear in the 228 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com